Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06SDP
|
|||
| Former ID |
DPR000073
|
|||
| Drug Name |
Melanotetan II
|
|||
| Synonyms |
Monorden; UNII-I60EH8GECX; I60EH8GECX; CHEMBL414883; CHEBI:556075; (1aR,2Z,4E,14R,15aR)-8-chloro-9,11-dihydroxy-14-methyl-1a,14,15,15a-tetrahydro-6H-oxireno[e][2]benzoxacyclotetradecine-6,12(7H)-dione; Monorderne; RDC; C18H17ClO6; Radisicol; Radicolol; Monorden A; RHI-12648; Microlactone, 1; 3cgy; NSC-294404; 4egk; 2wer; NSC 294404; 2zbk; 1bgq; (+)-Monorden A; Radicicol R 2146; 2q8i; SCHEMBL868832; BDBM15361; MolPort-003-959-447; HMS3648C16; BDBM227589; 6H-Oxireno(e)(2)benzoxacyclotetradecin-6,12(7H)-dione, 8-chlor
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Preclinical | [1] | |
| Sexual dysfunction [ICD-11: HA00-HA01] | Preclinical | [1] | ||
| Type-2 diabetes [ICD-11: 5A11] | Preclinical | [1] | ||
| Company |
Clinuvel Pharmaceuticals
|
|||
| PubChem Substance ID |
811127, 831350, 6436135, 7890236, 12015279, 14716680, 16476901, 24899351, 26703315, 26717606, 34178996, 46391541, 46515660, 47211693, 49703995, 57570978, 58686944, 87323562, 87557234, 87557487, 87557647, 91722227, 104234190, 134339525, 134340418, 135055217, 135685860, 137865009, 140305216, 162223526, 170481460, 175607782, 208012627, 227138252, 241179499, 241182551, 241375519, 252457202, 252469187
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocortin receptor 3 (MC3R) | Target Info | Agonist | [1] |
| Melanocortin receptor 4 (MC4R) | Target Info | Agonist | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.